Pictet Asset Management
IONS icon

Pictet Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Pictet Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107M Buy
1,434,995
+16,504
+1% +$1.3M 0.11% 201
2025
Q4 		$112M Buy
1,418,491
+25,367
+2% +$1.91M 0.11% 202
2025
Q3 		$90.5M Buy
1,393,124
+784,484
+129% +$38.3M 0.09% 229
2025
Q2 		$24.2M Sell
608,640
-9,910
-2% -$324K 0.02% 464
2025
Q1 		$19.2M Sell
618,550
-2,248
-0.4% -$73.6K 0.02% 507
2024
Q4 		$21.7M Sell
620,798
-682,703
-52% -$25.5M 0.02% 482
2024
Q3 		$52.7M Sell
1,303,501
-1,106,453
-46% -$51.5M 0.06% 281
2024
Q2 		$115M Sell
2,409,954
-1,329,803
-36% -$54.5M 0.13% 175
2024
Q1 		$163M Buy
3,739,757
+221,440
+6% +$10.6M 0.18% 149
2023
Q4 		$178M Buy
3,518,317
+277,383
+9% +$13.3M 0.2% 133
2023
Q3 		$147M Buy
+3,240,934
New +$134M 0.18% 148

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management's IONS Position: Q1 2026 in Review

Pictet Asset Management increased its Ionis Pharmaceuticals (IONS) stake by 1.2% in Q1 2026, buying an estimated $1.3M and bringing the position to 1,434,995 shares worth $107M. The position accounts for 0.11% of the portfolio, ranked #201.

Pictet Asset Management first reported a position in IONS in Q3 2023 and has held it in 11 quarters since. The position peaked at $178M in Q4 2023. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Pictet Asset Management held 1,434,995 shares of Ionis Pharmaceuticals worth $107M as of Q1 2026.
  • Pictet Asset Management bought 16,504 Ionis Pharmaceuticals shares in Q1 2026, an estimated $1.3M.
  • Ionis Pharmaceuticals made up 0.11% of Pictet Asset Management's portfolio in Q1 2026, its #201 holding.
  • Pictet Asset Management first reported a position in Ionis Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Ionis Pharmaceuticals position peaked at $178M in Q4 2023.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.